FUSION IMPLANTS LTD.

Company Registration Number:
08437560 (England and Wales)

Unaudited abridged accounts for the year ended 30 June 2024

Period of accounts

Start date: 01 July 2023

End date: 30 June 2024

FUSION IMPLANTS LTD.

Contents of the Financial Statements

for the Period Ended 30 June 2024

Balance sheet
Notes

FUSION IMPLANTS LTD.

Balance sheet

As at 30 June 2024


Notes

2024

2023


£

£
Fixed assets
Intangible assets: 3 833 0
Tangible assets: 4 18,549 3,539
Investments:   0 0
Total fixed assets: 19,382 3,539
Current assets
Stocks: 134,373 55,927
Debtors: 5 120,248 59,232
Cash at bank and in hand: 7,028 27,116
Investments:   0 0
Total current assets: 261,649 142,275
Creditors: amounts falling due within one year: 6 (131,708) (31,126)
Net current assets (liabilities): 129,941 111,149
Total assets less current liabilities: 149,323 114,688
Creditors: amounts falling due after more than one year: 7 (57,832) (65,333)
Total net assets (liabilities): 91,491 49,355
Capital and reserves
Called up share capital: 5 5
Share premium account: 40,006 40,006
Profit and loss account: 51,480 9,344
Shareholders funds: 91,491 49,355

The notes form part of these financial statements

FUSION IMPLANTS LTD.

Balance sheet statements

For the year ending 30 June 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 13 March 2025
and signed on behalf of the board by:

Name: Daniel Jones
Status: Director

The notes form part of these financial statements

FUSION IMPLANTS LTD.

Notes to the Financial Statements

for the Period Ended 30 June 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Intangible fixed assets and amortisation policy

Patents are valued at cost less accumulated amortisation. Amortisation is calculated to write off the cost in equal annual instalments over their estimated useful life of 18 months.

Other accounting policies

Stocks Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, in bringing the stocks to their present location and condition. At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

FUSION IMPLANTS LTD.

Notes to the Financial Statements

for the Period Ended 30 June 2024

2. Employees

2024 2023
Average number of employees during the period 5 5

FUSION IMPLANTS LTD.

Notes to the Financial Statements

for the Period Ended 30 June 2024

3. Intangible Assets

Total
Cost £
At 01 July 2023 8,536
Additions 2,500
At 30 June 2024 11,036
Amortisation
At 01 July 2023 8,536
Charge for year 1,667
At 30 June 2024 10,203
Net book value
At 30 June 2024 833
At 30 June 2023 0

FUSION IMPLANTS LTD.

Notes to the Financial Statements

for the Period Ended 30 June 2024

4. Tangible Assets

Total
Cost £
At 01 July 2023 34,356
Additions 22,285
At 30 June 2024 56,641
Depreciation
At 01 July 2023 30,817
Charge for year 7,275
At 30 June 2024 38,092
Net book value
At 30 June 2024 18,549
At 30 June 2023 3,539

FUSION IMPLANTS LTD.

Notes to the Financial Statements

for the Period Ended 30 June 2024

5. Debtors

2024 2023
££
Debtors due after more than one year: 0 0

FUSION IMPLANTS LTD.

Notes to the Financial Statements

for the Period Ended 30 June 2024

6. Creditors: amounts falling due within one year note

Trade creditors £92,000 (2023: £0) Taxation £22,789 (2023: £19,387) Other creditors £16,919 (2023: £11,739)

FUSION IMPLANTS LTD.

Notes to the Financial Statements

for the Period Ended 30 June 2024

7. Creditors: amounts falling due after more than one year note

Loan notes issued during the prior year £50,000 (2023: £50,000) Other loans £7,832 (£15,333)

FUSION IMPLANTS LTD.

Notes to the Financial Statements

for the Period Ended 30 June 2024

8. Related party transactions

Name of the related party:
Relationship:
Shareholders
Description of the Transaction: Included within other creditors are loan notes of £50,000 that are repayable in the sum of £16,666 to each of the majority share holders , the loans are interest free and repayable on demand.
£
Balance at 01 July 2023 50,000
Balance at 30 June 2024 50,000